Goldman Sachs Group Inc Catalyst Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
A detailed history of Goldman Sachs Group Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 3,135,473 shares of CPRX stock, worth $71.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,135,473
Previous 3,135,473
-0.0%
Holding current value
$71.5 Million
Previous $76 Million
-0.0%
% of portfolio
0.01%
Previous 0.01%
Shares
21 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$426 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$194 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$126 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$78.1 Million2.1% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.96MShares$67.4 Million0.12% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.35B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...